-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KPI-012 in Persistent Corneal Epithelial Defects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KPI-012 in Persistent Corneal Epithelial Defects report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KPI-012 in Persistent Corneal Epithelial Defects Drug Details: KPI-012...
-
Product Insights
NewPersistent Corneal Epithelial Defects – Drugs In Development, 2024
Empower your strategies with our Persistent Corneal Epithelial Defects – Drugs In Development, 2024 report and make more profitable business decisions. Persistent corneal epithelial defects result from failure of re-epithelialization and complete healing within two weeks of corneal epithelial insult, even after conventional treatment. Persistent epithelial defects necessitate prompt and vigilant treatment to avoid associated potential complications, such as infection, vision loss, corneal scarring, melting, and even perforation The Persistent Corneal Epithelial Defects drugs in development market research report provide comprehensive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erenumab in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erenumab in Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erenumab in Pain Drug Details: Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erenumab in Rosacea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erenumab in Rosacea report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erenumab in Rosacea Drug Details: Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human...
-
Product Insights
NewIntegrin Alpha V – Drugs In Development, 2024
The Integrin Alpha V pipeline drugs market research report outlays comprehensive information on the Integrin Alpha V targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Ophthalmology, Gastrointestinal, and Musculoskeletal Disorders which include indications of Solid Tumor, Breast Cancer, Wet (Neovascular / Exudative) Macular Degeneration, Persistent Corneal Epithelial Defects, Primary Sclerosing Cholangitis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Fibrosis,...
-
Product Insights
NewIntegrin Beta 3 – Drugs In Development, 2024
The Integrin Beta 3 pipeline drugs market research report outlays comprehensive information on the Integrin Beta 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Ophthalmology, Cardiovascular, and Dermatology which include indications of Breast Cancer, Glioblastoma Multiforme (GBM), Wet (Neovascular / Exudative) Macular Degeneration, Persistent Corneal Epithelial Defects, Thrombosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease),...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atacicept in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atacicept in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atacicept in IgA Nephropathy (Berger's Disease) Drug Details: Atacicept...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Memantine Hydrochloride in Vascular Dementias
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Memantine Hydrochloride in Vascular Dementias report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Memantine Hydrochloride in Vascular Dementias Drug Details: Memantine Hydrochloride (Namenda...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lebrikizumab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lebrikizumab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lebrikizumab in Atopic Dermatitis (Atopic Eczema) Drug Details: Lebrikizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tenecteplase in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tenecteplase in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenecteplase in Acute Ischemic Stroke Drug Details: Tenecteplase (Metalyse, Tnkase)...